PI3K at the crossroads of tumor angiogenesis signaling pathways.
Tumors need blood vessels for their growth, thus providing the rationale for antiangiogenic therapy in cancer treatment. However, intrinsic and acquired resistance and low response rates have turned out to be major limitations of antiangiogenic therapy. This emphasizes the need to further understand how the vasculature in cancer can be targeted. Although endothelial cells (ECs) rely on multiple growth factors and cytokines to grow, antiangiogenic therapies have mainly centered on targeting vascular endothelial growth factor (VEGF). Phosphoinositide 3-kinases (PI3Ks) form a family of 8 isoenzymes with non-redundant functions in normal biology and cancer. The subgroup of class I PI3Ks are situated at the crossroad of a plethora of proangiogenic signals and control cell growth, survival, motility, and metabolism. These isoenzymes have pleiotropic roles in the tumor microenvironment, including cell-autonomous functions in ECs, underscoring the complexity of targeting this pathway in cancer. Here, we describe how the PI3K axis influences angiogenesis in different cell compartments and summarize the diversity of vascular responses to PI3K inhibition. Targeting PI3K signaling by isoform-selective inhibitors, together with readjusting the current doses below the maximum tolerated dose, may improve clinical responses to class I PI3K anticancer agents.
Vascular Signalling Lab; Angiogenesis Unit, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) ; Barcelona, Spain.
Adriana
A
Soler
Vascular Signalling Lab; Angiogenesis Unit, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) ; Barcelona, Spain.
Ana
A
Angulo-Urarte
Vascular Signalling Lab; Angiogenesis Unit, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) ; Barcelona, Spain.
Mariona
M
Graupera
PI3K; VEGF; angiogenesis; tumor-extrinsic and intrinsic roles